ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
|
|
| Not yet recruiting | 3 | 234 | US | Clofazimine Inhalation Suspension, MNKD-101, Placebo | Mannkind Corporation | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 08/26 | 12/28 | | |
